Last reviewed · How we verify
Insulin Degludec and Insulin Aspart — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Insulin Degludec and Insulin Aspart (Insulin Degludec and Insulin Aspart) — Huashan Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Insulin Degludec and Insulin Aspart TARGET | Insulin Degludec and Insulin Aspart | Huashan Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Insulin Degludec and Insulin Aspart CI watch — RSS
- Insulin Degludec and Insulin Aspart CI watch — Atom
- Insulin Degludec and Insulin Aspart CI watch — JSON
- Insulin Degludec and Insulin Aspart alone — RSS
Cite this brief
Drug Landscape (2026). Insulin Degludec and Insulin Aspart — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-degludec-and-insulin-aspart. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab